2nd RICHEN GROUP OPEN COMPETITION
RICHEN EUROPE is the European operating branch of the RICHEN GROUP, a major international group of medical device manufacturers with a global commitment. The company specializes in developing the best solutions for patients in the field of gastroenterology. Over the years our R&D department has excelled in the design and development of high-performance safe equipment and reagents for the diagnosis of Helicobacter pylori infection.
Click on the banner above to read more about the
2nd Open Competition 2022-2023 for research in the field of Helicobacter pylori
1st RICHEN GROUP OPEN COMPETITION
On behalf of The Richen Group, in collaboration with the EHMSG Members, we are glad to announce that 2 projects have been selected for the research development phase of the Richen Open Competition for research in the field of Helicobacter pylori 2021-2022:
1) Study on the detection of H. pylori with a 13C urea breath test after bariatric surgery: from an undetectable pathogen to a treatable diagnosis.
By: Philip Plaeke, Annemieke Smet
From: Antwerp University Hospital, Antwerp, Belgium
2) The predictor role of Urea Breath testing in Italian and Chinese subjects with presumptive HelicobacterPylori infection with or without previous COVID-19 infection
By: Leonilde Bonfrate, Piero Portincasa
From: Clinica Medica “A. Murri”, University of Bari, Italy
The findings of these research projects will be made available during the next year's workshop in Glasgow, United Kingdom, where a final winner's selection will take place.
Javier P. Gisbert, Francis Mégraud, Colm O'Morain, Leticia Moreira, Olga P. Nyssen and Ignasi Puig
The great diversity of regimens and treatment lines and the different efficacy of these, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and diagnostic-therapeutic strategies.
The evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency.
To obtain a database registering systematically a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection.
To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries.
To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori.
To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection.
To allow the development of partial and specific analysis by the participating researchers.